Ovarian cancer stem cell markers: Prognostic and therapeutic implications

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 1-7

  Burgos Ojeda, Daniela ^a   Rueda, Bo R ^b   Buckanovich, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer stem cells; Ovarian cancer; Prognosis; Stem cell hierarchy; Therapeutics

Indexed keywords

ALDEHYDE DEHYDROGENASE; CARBOPLATIN; CD133 ANTIGEN; CD24 ANTIGEN; CISPLATIN; DISULFIRAM; DOCETAXEL; HERMES ANTIGEN; IMATINIB; PACLITAXEL; PLATINUM COMPLEX; STEM CELL FACTOR RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CYSTADENOCARCINOMA; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METASTASIS; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; SHORT SURVEY; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84861460366     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.002     Document Type: Review

References (87)

1. Medema J.P., Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011, 474:318-326.
2. Vermeulen L., Sprick M.R., Kemper K., Stassi G., Medema J.P. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008, 15:947-958.
3. Silva I.A., Bai S., McLean K., Yang K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R.K., Wicha M.S., Buckanovich R.J. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011, 71:3991-4001.
4. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S., Marks J.R., Berchuck A., Murphy S.K. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
5. Landen C.N., Goodman B., Katre A.A., Steg A.D., Nick A.M., Stone R.L., Miller L.D., Mejia P.V., Jennings N.B., Gershenson D.M., Bast R.C., Coleman R.L., Lopez-Berestein G., Sood A.K. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 2010, 9:3186-3199.
6. Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., Bapat S.A. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
7. Murphy S.K. Targeting ovarian cancer-initiating cells. Anticancer Agents Med. Chem. 2010, 10:157-163.
8. Naora H. Developmental patterning in the wrong context: the paradox of epithelial ovarian cancers. Cell Cycle 2005, 4:1033-1035.
9. Fleming J.S., Beaugiã© C.R., Haviv I., Chenevix-Trench G., Tan O.L. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol. Cell. Endocrinol. 2006, 247:4-21.
10. Helbing T., Rothweiler R., Ketterer E., Goetz L., Heinke J., Grundmann S., Duerschmied D., Patterson C., Bode C., Moser M. BMP activity controlled by BMPER regulates the proinflammatory phenotype of endothelium. Blood 2011.
11. Osada A., Kiyozumi D., Tsutsui K., Ono Y., Weber C.N., Sugimoto N., Imai T., Okada A., Sekiguchi K. Expression of MAEG, a novel basement membrane protein, in mouse hair follicle morphogenesis. Exp. Cell Res. 2005, 303:148-159.
12. Dale L., Evans W., Goodman S.A. Xolloid-related: a novel BMP1/Tolloid-related metalloprotease is expressed during early Xenopus development. Mech. Dev. 2002, 119:177-190.
13. Chan R.W.S., Gargett C.E. Identification of label-retaining cells in mouse endometrium. Stem Cells 2006, 24:1529-1538.
14. Sasson I.E., Taylor H.S. Stem cells and the pathogenesis of endometriosis. Ann. NY Acad. Sci. 2008, 1127:106-115.
15. Oberauer R., Rist W., Lenter M.C., Hamilton B.S., Neubauer H. EGFL6 is increasingly expressed in human obesity and promotes proliferation of adipose tissue-derived stromal vascular cells. Mol. Cell Biochem. 2010, 343:257-269.
16. Gao M.Q., Choi Y.P., Kang S., Youn J.H., Cho N.H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
17. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69:9245-9253.
18. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., Olweus J., Kearney J., Buck D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
19. Hristov M., Erl W., Weber P.C. Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med. 2003, 13:201-206.
20. Singh S.K., Clarke I.D., Hide T., Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 2004, 23:7267-7273.
21. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
22. Hess D.A., Wirthlin L., Craft T.P., Herrbrich P.E., Hohm S.A., Lahey R., Eades W.C., Creer M.H., Nolta J.A. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006, 107:2162-2169.
23. Gentry T., Deibert E., Foster S.J., Haley R., Kurtzberg J., Balber A.E. Isolation of early hematopoietic cells, including megakaryocyte progenitors, in the ALDH-bright cell population of cryopreserved, banked UC blood. Cytotherapy 2007, 9:569-576.
24. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
25. Ferrandina G., Martinelli E., Petrillo M., Prisco M.G., Zannoni G., Sioletic S., Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009, 9:221.
26. Ferrandina G., Bonanno G., Pierelli L., Perillo A., Procoli A., Mariotti A., Corallo M., Martinelli E., Rutella S., Paglia A., Zannoni G., Mancuso S., Scambia G. Expression of CD133-1 and CD133-2 in ovarian cancer. Int. J. Gynecol. Cancer 2008, 18:506-514.
27. Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., Roberts D.J., Seiden M.V., Scadden D.T., Rueda B.R., Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.
28. Kryczek I., Liu S., Roh M., Vatan L., Szeliga W., Wei S., Banerjee M., Mao Y., Kotarski J., Wicha M.S., Liu R., Zou W. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 2011.
29. Kusumbe A.P., Mali A.M., Bapat S.A. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem cells 2009, 27:498-508.
30. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
31. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
32. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
33. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 2007, 104:973-978.
34. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc. Natl. Acad. Sci. USA 2006, 103:11154-11159.
35. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005, 65:3025-3029.
36. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H., Nephew K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.
37. Luo L., Zeng J., Liang B., Zhao Z., Sun L., Cao D., Yang J., Shen K. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp. Mol. Pathol. 2011, 91:596-602.
38. Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., Silasi D.A., Steffensen K.D., Waldstrom M., Visintin I., Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166.
39. Alvero A.B., Fu H.H., Holmberg J., Visintin I., Mor L., Marquina C.C., Oidtman J., Silasi D.A., Mor G. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009, 27:2405-2413.
40. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69:9245-9253.
41. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9:50-63.
42. Choi Y.P., Shim H.S., Gao M.-Q., Kang S., Cho N.H. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011, 307:62-71.
43. Wei X., Dombkowski D., Meirelles K., Pieretti-Vanmarcke R., Szotek P.P., Chang H.L., Preffer F.I., Mueller P.R., Teixeira J., MacLaughlin D.T., Donahoe P.K. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl. Acad. Sci. USA 2010, 107:18874-18879.
44. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes. Dev. 2009, 23:2563-2577.
45. Anglesio M.S., George J., Kulbe H., Friedlander M., Rischin D., Lemech C., Power J., Coward J., Cowin P.A., House C.M., Chakravarty P., Gorringe K.L., Campbell I.G., Okamoto A., Birrer M.J., Huntsman D.G., de Fazio A., Kalloger S.E., Balkwill F., Gilks C.B., Bowtell D.D. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 2011, 17:2538-2548.
46. Tsuda H., Ito Y.M., Ohashi Y., Wong K.K., Hashiguchi Y., Welch W.R., Berkowitz R.S., Birrer M.J., Mok S.C. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin. Cancer Res. 2005, 11:6880-6888.
47. Ma L., Lai D., Liu T., Cheng W., Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:593-602.
48. Steffensen K.D., Alvero A.B., Yang Y., Waldstrom M., Hui P., Holmberg J.C., Silasi D.A., Jakobsen A., Rutherford T., Mor G. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J. Oncol. 2011, 2011:620523.
49. Deng S., Yang X., Lassus H., Liang S., Kaur S., Ye Q., Li C., Wang L.P., Roby K.F., Orsulic S., Connolly D.C., Zhang Y., Montone K., Butzow R., Coukos G., Zhang L. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010, 5:e10277.
50. Chang B., Liu G., Xue F., Rosen D.G., Xiao L., Wang X., Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod. Pathol. 2009, 22:817-823.
51. Zhang J., Guo X., Chang D.Y., Rosen D.G., Mercado-Uribe I., Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod. Pathol. 2011.
52. A.D. Steg, K.S. Bevis, A.A. Katre, A. Ziebarth, R.D. Alvarez, K. Zhang, M.B. Conner, C.N. Landen, Stem cell pathways contribute to clinical chemoresistance in ovarian cancer, Clin. Cancer Res. 2011.
53. Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C., Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 2002, 161:1215-1221.
54. Piotrowicz R.S., Damaj B.B., Hachicha M., Incardona F., Howell S.B., Finlayson M. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol. Cancer Ther. 2011, 10:2072-2082.
55. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., Ravoori M., Kundra V., Freedman R.S., Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
56. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., Dvash R., Landsman-Milo D., Bremer M.G., Moghimi S.M., Peer D. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J. Control Release 2011, 156:231-238.
57. Casagrande F., Cocco E., Bellone S., Richter C.E., Bellone M., Todeschini P., Siegel E., Varughese J., Arin-Silasi D., Azodi M., Rutherford T.J., Pecorelli S., Schwartz P.E., Santin A.D. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117:5519-5528.
58. Serafino A., Zonfrillo M., Andreola F., Psaila R., Mercuri L., Moroni N., Renier D., Campisi M., Secchieri C., Pierimarchi P. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr. Cancer Drug Targets 2011, 11:572-585.
59. De Stefano I., Battaglia A., Zannoni G.F., Prisco M.G., Fattorossi A., Travaglia D., Baroni S., Renier D., Scambia G., Ferlini C., Gallo D. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemot. Pharmacol. 2011, 68:107-116.
60. Somasunderam A., Thiviyanathan V., Tanaka T., Li X., Neerathilingam M., Lokesh G.L., Mann A., Peng Y., Ferrari M., Klostergaard J., Gorenstein D.G. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 2010, 49:9106-9112.
61. Slomiany M.G., Dai L., Tolliver L.B., Grass G.D., Zeng Y., Toole B.P. Inhibition of functional hyaluronan-cd44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin. Cancer Res. 2009, 15:7593-7601.
62. Li S.D., Howell S.B. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol. Pharm. 2010, 7:280-290.
63. Hassan H.T. C-kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk. Res. 2009, 33:5-10.
64. Juretzka M., Hensley M.L., Tew W., Konner J., Aghajanian C., Leitao M., Iasonos A., Soslow R., Park K., Sabbatini P. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur. J. Gynaecol. Oncol. 2008, 29:568-572.
65. Schilder R.J., Sill M.W., Lee R.B., Shaw T.J., Senterman M.K., Klein-Szanto A.J., Miner Z., Vanderhyden B.C. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 2008, 26:3418-3425.
66. Matei D., Chang D.D., Jeng M.-H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin. Cancer Res. 2004, 10:681-690.
67. Margalit E., Sunness J.S., Green W.R., Kelman S.E., Schachat A.P., Fiergang D., Allikmets R. Stargardt disease in a patient with retinoblastoma. Arch. Ophthalmol. 2003, 121:1643-1646.
68. Li H.K., Shields J.A., Shields C.L., Maguire J.I., Garg S.J. Retinal vasoproliferative tumour as the initial manifestation of retinitis pigmentosa. Clin. Exp. Ophthalmol. 2008, 36:895-897.
69. Yang C., Liu Y., Lu X., Qian F., Zhao L. Sporadic bilateral retinitis pigmentosa sine pigmento associated with atypical Peutz-Jeghers syndrome. Can. J. Ophthalmol. 2010, 45:184-185.
70. Bourseau-Guilmain E., Griveau A., Benoit J.P., Garcion E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One 2011, 6:e25515.
71. Takenobu H., Shimozato O., Nakamura T., Ochiai H., Yamaguchi Y., Ohira M., Nakagawara A., Kamijo T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30:97-105.
72. Dong L., Qi N., Ge R.M., Cao C.L., Lan F., Shen L. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells. Neurosci. Lett. 2010, 484:210-214.
73. Feng H.L., Liu Y.Q., Yang L.J., Bian X.C., Yang Z.L., Gu B., Zhang H., Wang C.J., Su X.L., Zhao X.M. Expression of CD133 correlates with differentiation of human colon cancer cells. Cancer Biol. Ther. 2010, 9:216-223.
74. Yao J., Zhang T., Ren J., Yu M., Wu G. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol. Rep. 2009, 22:781-787.
75. Xu M., Rettig M., Sudlow G., Wang B., Akers W., Cao D., Mutch D., Dipersio J., Achilefu S. Preclinical evaluation of mab CC188 for ovarian cancer imaging. Int. J. Cancer 2011.
76. Ferrandina G., Petrillo M., Bonanno G., Scambia G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13:823-837.
77. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011, 7:292-306.
78. Kast R.E., Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr. Stem Cell Res. Ther. 2009, 4:314-317.
79. Morrison B.W., Doudican N.A., Patel K.R., Orlow S.J. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res. 2010, 20:11-20.
80. Lin J., Haffner M.C., Zhang Y., Lee B.H., Brennen W.N., Britton J., Kachhap S.K., Shim J.S., Liu J.O., Nelson W.G., Yegnasubramanian S., Carducci M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2011, 71:333-343.
81. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., Armesilla A.L., Xu B., Cassidy J., Darling J.L., Wang W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574.
82. Verma S., Stewart D.J., Maroun J.A., Nair R.C. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am. J. Clin. Oncol. 1990, 13:119-124.
83. Lee J.H., Kim S.H., Lee E.S., Kim Y.S. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol. Rep. 2009, 22:1149-1156.
84. Su D., Deng H., Zhao X., Zhang X., Chen L., Chen X., Li Z., Bai Y., Wang Y., Zhong Q., Yi T., Qian Z., Wei Y. Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 2009, 11:642-652.
85. Chang H.L., Pieretti-Vanmarcke R., Nicolaou F., Li X., Wei X., MacLaughlin D.T., Donahoe P.K. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol. Oncol. 2011, 120:128-134.
86. McLean K., Gong Y., Choi Y., Deng N., Yang K., Bai S., Cabrera L., Keller E., McCauley L., Cho K.R., Buckanovich R.J. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Invest. 2011, 121:3206-3219.
87. McCann C.K., Growdon W.B., Kulkarni-Datar K., Curley M.D., Friel A.M., Proctor J.L., Sheikh H., Deyneko I., Ferguson J.A., Vathipadiekal V., Birrer M.J., Borger D.R., Mohapatra G., Zukerberg L.R., Foster R., MacDougall J.R., Rueda B.R. Inhibition of hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One 2011, 6:e28077.